Common questions about Evicto (FAQ)
Q: What is the main medical condition Evicto is officially used to treat?
A: Official product information states Evicto is primarily indicated for the prevention of heartworm disease, caused by Dirofilaria immitis. Additionally, it is used for the treatment and control of various parasites, including fleas, ear mites, biting lice, roundworm, and hookworm, depending on the target animal species.
Q: Is Evicto approved for use in children or adolescents?
A: Evicto is a veterinary medicine and regulatory documents explicitly state it is Not for human use. The product is approved for use in dogs and puppies 6 weeks of age and older, and in cats and kittens 8 weeks of age and older.
Q: How did Evicto perform compared to a placebo in the clinical trials?
A: Clinical studies reported positive findings reviewed by regulatory agencies. For example, evidence indicates that in controlled laboratory studies, the product killed over 98% of adult fleas within 36 hours of application.
Q: What is the simple explanation of Evicto’s general mechanism of action?
A: The active ingredient, selamectin, is designed to work by targeting specific nerve receptors (GABA-gated chloride channels) unique to the parasite. This neurological disruption results in paralysis and subsequent death of the target parasites.
Q: What is the longest period of time Evicto was studied for in its main trials?
A: The product is intended and studied for continuous, monthly administration for year-round prevention of heartworm and control of fleas. The evidence supports ongoing use based on a defined time interval to maintain efficacy.
Q: What does Evicto's regulatory class (e.g., JAK inhibitor, TNF blocker) mean?
A: Evicto belongs to the Avermectin class of antiparasitic medication. This classification refers to the chemical structure and the core biological target of the active ingredient, which is highly effective against invertebrates.
Q: Where can I find published studies about the effectiveness of Evicto?
A: Information on clinical trials and effectiveness is made public through official regulatory channels. This data can be found in documents such as the FDA Freedom of Information (FOI) Summary and the EMA Committee for Veterinary Medicinal Products (CVMP) Assessment Report.
Q: Is Evicto classified as a biologic medicine?
A: No, official documents clarify that Evicto is not classified as a biologic. The active ingredient, selamectin, is a small-molecule chemical compound that belongs to the avermectin class of antiparasitic drugs.
Q: What are the most commonly reported side effects of Evicto?
A: According to the official product information, common side effects include temporary hair loss, clumping of hair, or a white powdery residue at the site of application. A comprehensive list of rare adverse reactions, such as vomiting, diarrhea, and lethargy, is available in the dedicated 'Possible side effects and safety information' section.
Q: Does Evicto cause people to gain weight?
A: Evicto is strictly a veterinary medicine and is not approved for use in humans. Furthermore, official regulatory reports for the target animal species (dogs and cats) do not list weight gain as a common adverse reaction.
Q: Is a headache a listed side effect of Evicto?
A: Headache is not listed as an adverse reaction for the target animal species. Official warnings caution that accidental human skin contact may cause localized reactions such as skin irritation, hives, and itching.
Q: What does official guidance say about using Evicto in older adults (e.g., over 65)?
A: The product is approved for use in adult animals and regulatory labels do not specify an upper age restriction. However, official precautions advise caution when using the product in animals that are sick, debilitated, or underweight.
Q: What information is available about using Evicto during pregnancy?
A: Studies indicate the product may be used in pregnant, breeding, and lactating female dogs and cats. Official product information includes data on the use of Evicto in these populations.
Q: What are the official signs of a severe allergic reaction related to Evicto?
A: Although rare, severe adverse reactions reported include neurological signs such as muscle tremors, ataxia (incoordination), convulsions, or collapse. Official warnings state that the product is contraindicated for animals with a known hypersensitivity to the product.
Q: What does official drug information state about suddenly stopping the use of Evicto?
A: The official guidance addresses the procedure for a missed dose. Stopping the regular monthly regimen may result in the loss of protection against heartworm and other parasites.
Q: Is Evicto a recently approved medicine?
A: Evicto is a newer authorization of the active ingredient selamectin. Regulatory filings show the product was first authorized in the European Union in 2019, and a generic equivalent was approved in the US in January 2024.
Q: Are there any mandatory monitoring tests required while a person is taking Evicto?
A: Official precautions require that all animals 6 months of age or older be tested for existing heartworm infections before administration of the preventative regimen.
Q: Is there any information about Evicto's effects on fertility?
A: Regulatory studies of breeding male and female dogs and cats reported no adverse effects on fertility.
Q: What specific pre-existing health conditions disqualify someone from using Evicto?
A: According to regulatory guidelines, Evicto is contraindicated in animals that are suffering from a concomitant disease, or those that are debilitated, sick, or underweight at the time of intended administration.
Q: Is feeling nauseous common when starting Evicto?
A: Vomiting or emesis is listed in regulatory documents as a rare adverse reaction in dogs and cats. This reaction may occur if the animal is able to lick the product off the application site.
Q: What is the regulatory designation of Evicto (e.g., orphan drug)?
A: Evicto is officially designated as a generic or hybrid version of the original selamectin product by regulatory authorities. This classification relates to its path to market authorization.
Q: What percentage of participants in studies reported a specific side effect?
A: While full study data is extensive, official labeling notes that temporary hair loss at the application site occurred in about 1% of cats. Other neurological signs were generally observed in less than 0.5% of treated animals.
Q: What official drug warnings are associated with Evicto’s use?
A: Official warnings include the statement that the product is Not for human use and must be kept out of the reach of children. The label also warns that the product is highly flammable and contains a warning regarding application to broken skin.
Q: What is the purpose of the initial testing that must be done before starting Evicto?
A: Initial testing is necessary to confirm the animal's heartworm status. The product is designed to prevent new heartworm infections, but it is not intended to treat existing adult heartworms.
Q: What information is available about the effects of Evicto on mental health or mood?
A: Regulatory safety reports note that the product may rarely cause neurological signs, which include changes like lethargy, ataxia (incoordination), muscle tremors, or convulsions.
